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Abstract: Rheumatoid arthritis and osteoarthritis are the main diseases that imply an inflammatory process at the joints 
involving the articular cartilage. Recently, mesenchymal stem cells (MSCs) derived from perinatal tissues were consid-
ered good candidates for cellular therapy of musculoskeletal and orthopaedic diseases, since they can differentiate into 
multiple cell types and are an easily accessible cellular source. Therefore, several protocols exist on the differentiation of 
mesenchymal stem cells of different origins into osteoblasts and chondrocytes. Another key feature of MSCs is their ca-
pacity to modulate the immune system responses in vitro and in vivo. This may have critical outcomes in diseases of the 
musculoskeletal system where an inflammatory or autoimmune process is at the basis of the main disease. 
In the present paper, after isolation of MSCs from Wharton’s Jelly (WJ-MSCs), we performed the three standard differen-
tiation protocols. The acquisition of the differentiated phenotype was demonstrated by the specific histological stains. As 
the main objective of this work, we determined the expression of immunomodulatory molecules (by immunohistochemis-
try and qualitative RT-PCR), both in undifferentiated cells and after differentiation. We demonstrated for the first time 
that immune-related molecules (as B7-H3/CD276 and HLA-E) which have been characterized in undifferentiated MSCs, 
are also expressed by the differentiated progeny. This strongly suggests that also after the acquisition of a mature pheno-
type, WJ-MSCs-derived cells may maintain their immune privilege. This evidence, which deserves much work to be con-
firmed in vivo and in other MSCs populations, may provide a formal proof of the good results globally achieved with WJ-
MSCs as cellular therapy vehicle. 
Keywords: Regenerative medicine, mesenchymal stem cells, umbilical cord, Wharton’s jelly, immune modulation, tissue re-
pair, osteogenic differentiation, adipogenic differentiation, chondrogenic differentiation.  
INTRODUCTION 
 As reported by World Health Organization (WHO), the 
main causes of disability in the world are rheumatic, ortho-
paedic and musculoskeletal diseases. Rheumatoid arthritis 
(RA) and osteoarthritis (OA) are two diseases responsible of 
inflammation of the joints [1].  
 In OA, inflammatory process represents the result of 
pathogenetic condition, while in RA it is the main cause [2].  
 Both diseases, as well as isolated chondral and osteo-
chondral disorders, involve injuries to articular cartilage, a 
type of hyaline cartilage composed by small chondro 
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cytes and a granular matrix, where is possible to distinguish 
three different classes of macromolecules: fibrillar and  
non-fibrillar collagens, collagenous proteins and proteogly 
[3-4]. 
 It has been demonstrated that an imbalance between cata-
bolic and anabolic functions of the chondrocytes may 
determine a cartilage injury. In addition, since chondrocytes 
are fed by diffusion via the synovial fluid, both growth and 
repair of cartilage are very slow [5]. 
 For these reasons, some research groups investigated 
alternative methods to promote cartilage formation (such as 
osteotomy, joint distraction, implants of growth factors or 
artificial matrices), or to replace the chondrocytes by cell 
transplantation [6-7].  
Chondrogenesis and Chondrocyte Differentiation Process 
 Chondrogenesis is a dynamic cellular process that in-
volves the formation of hyaline, fibrous and elastic cartilage 
both during embryogenesis and in adult life. The process of 
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chondrogenesis begins with aggregation and condensation of 
mesenchymal cells with the involvement of bone morphoge-
netic proteins (BMPs) [8]. In this phase, the condensed mes-
enchyme expresses some extracellular matrix and cell adhe-
sion molecules such as IIa splice form of type II collagen 
[Col2a1(IIa)] [9, 10], N-cadherin (Ncad) [11], neural cell 
adhesion molecule (Ncam1) [12], tenascin C (Tnc) [13], and 
SRY-box 9 (Sox9), transcription factor involved in the early 
stages of chondrogenesis [14].  
 Subsequently, the chondrogenesis process is character-
ized by early chondrocyte differentiation and development of 
the cartilage template and by chondrocyte maturation and 
hypertrophy. If osteogenesis has to follow, during maturation 
steps, the chondrocytes differentiate, mineralize and undergo 
apoptosis. When the chondrocytes die, cartilage matrix de-
posits constitute the basis for mineral deposition and bone 
formation. In this phase, degraded cartilage will be invaded 
by blood vessels establishing the bone marrow cavity [15]. 
Articular Cartilage Tissue Engineering and Factors In-
volved in Chondrogenic Differentiation  
 Hyaline cartilage of the limb and trunk skeleton derives 
from differentiation of mesenchymal stem cells that con-
dense into clusters of cartilage cells (chondrocytes). Physio-
logically, this cartilage type is susceptible to both normal and 
pathologic stress [15]. In particular, articular cartilage may 
undergo degenerative processes involving focal and progres-
sive cartilage loss. The main risk factors are linked to genetic 
background, obesity, advanced age, ethinicity, osteochondral 
and chondral lesions and OA. 
 In the last years, tissue engineering was considered the 
main approach for repair of articular cartilage lesions. 
Autologous, heterotypic and allogenic chondrocytes were 
expanded in culture [16]. 
 The presence in culture media of specific growth factors 
such as members of TGF- (transforming growth factor –) 
superfamily, insulin like growth factor (IGF), hepatocyte 
growth factor (HGF) and BMPs can influence the chondro-
cyte phenotype [17]. BMPs belong to the TGF- superfamily 
and can promote ectopic cartilage and bone formation 
through a direct regulation of the expression of chondrocyte 
genes [18]. 
 Bone morphogenetic protein-2 (BMP-2) together with 
TGF-, can influence the synthesis of type II collagen, the 
main marker to evaluate acquisition of chondrocyte pheno-
type. Some authors demonstrated that in costal embryonic 
mouse chondrocytes, the presence in culture of BMP-2 in-
duced the expression of type IIB and -10 integrin, while 
TGF-1 potentiated the expression of type IIA and 11 in-
tegrin [19, 20].  
 Another work highlighted that the addition of BMP-2 in 
monolayer cultures of nasal chondrocytes, could reactivate 
the chondrogenic expression programme, in particular induc-
ing the expression of type II collagen gene by enhancing 
DNA-binding of the SOX transcription factors [21]. 
 Recently, some research groups suggested the use of 
adult stem cells to derive chondrocyte-like cells. In particu-
lar, mesenchymal stem cells are considered as good candi-
dates for chondrocyte differentiation. In addition, in recent 
years the interest for perinatal tissues-derived MSCs is in-
creased considering that these cells may be easily sourced 
[6]. 
 To promote chondrogenic differentiation, MSCs, after 
expansion in monolayer culture, need a three-dimensional 
(3D) environment to maintain the chondrocyte phenotype. 
Different 3D supports were proposed such as polymers, col-
lagen sponges or hydrogels, alginate beads and microspheres 
[22-25]. Alginate is a linear polysaccaride composed by re-
peated disaccharides of -D-mannuronic-acid and -L-
glucuronic acid. In the presence of calcium ions, the alginate 
can be cross-linked to generate a polymerized hydrogel. In 
this alginate solution, the cells allocate homogeneously [26]. 
The porosity of the hydrogel allows the diffusion of large 
molecules but not passive migration of cells [27]. 
Perinatal Mesenchymal Stem Cells: Characteristic Fea-
tures of WJ-MSCs 
 The first isolation of multipotent mesenchymal stromal 
cells from the bone marrow, was made in the 1970 by 
Friedenstein [28]. Mesenchymal stem cells (MSCs) are 
mononuclear, multipotent cells featuring a fibroblastoid 
morphology. They are defined as immature cells with the 
ability to self-renew and differentiate towards several cellu-
lar types such as osteoblasts, adipocytes and chondrocytes. 
MSCs grow on plastic surface and therefore can be quickly 
expanded in vitro for several passages [29]. Some research-
ers focused their attention on the use of MSCs derived from 
other easily accessible tissues with higher cellular yields. For 
example, bone marrow, is currently the common source of 
MSCs, even if the number of cells results very low [30] and 
decreases with donor age [31]. Umbilical cord blood, pla-
centa, amniotic membrane and umbilical cord stroma (Whar-
ton’s jelly) are some perinatal sources of MSCs. In literature, 
several studies demonstrated the differentiation ability of 
these cells in generating all cellular types derived from the 
three germ layers [32]. 
 Perinatal MSCs expresses a number of surface molecules 
such as CD105, CD73, CD106 (vascular cellular adhesion 
molecule-1), CD54 (intercellular adhesional molecule-1), 
CD44, CD90, CD29 and STRO-1, some cytokine receptors, 
molecules involved in immune responses such as canonical 
type I MHC (major histocompatibility complex) as HLA-A. 
MSCs do not express HLA-DR, a type II MHC, as well as 
hematopoietic stem cell markers such as CD45 and CD34. 
Markers such as CD31 (PECAM-1) and von Willenbrand 
factor (vWF) are specific for endothelial cells [33, 34] and 
we and others demonstrated their absence in WJ-MSCs [35]. 
 In the last years, our research group focused on Whar-
ton’s jelly-derived mesenchymal stem cells (WJ-MSCs). 
Wharton’s jelly, also known as intervascular stroma, is the 
main component of the extracellular matrix of human um-
bilical cord. It is composed by an amorphous substance rich 
in glycosamminoglycans (GAG) and proteoglycans, which 
hosts (in a classical view) two cellular types: myofibroblasts 
and fibroblast-like cells. The latter are commonly identified 
as the multipotent mesenchymal stem cells [36]. WJ-MSCs 
express all markers typical of mesenchymal stem cells but 
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express also CD117 (receptor of the stem cell factor). 
Moreover, our group demonstrated that WJ-MSCs are 
positive to the expression of some, endodermal markers such 
as GATA-4, GATA-5, GATA-6, hepatic nuclear factor-4 
(HNF-4), and mesodermal markers such as vimentin, and 
-smooth muscle actin, suggesting that these cells may dif-
ferentiate in several cellular types derived from all three 
germ layers [35, 37]. According to the International Society 
for Cellular Therapy, WJ-MSCs are multipotent because can 
differenteiate into osteoblasts, adipocytes and chondrocytes. 
Various in vitro and in vivo studies demonstrated that WJ-
MSCs cultured in a medium supplemented with chondrocyte 
inducers differentiate into chondrocyte-like cells [1]. 
Chondrogenic Differentiation by WJ-MSC in Culture 
and on Scaffolds  
 Arufe and colleagues, demonstrated that umbilical cord-
MSC may differentiate into chondrocyte-like cells when 
cultured in presence of ascorbic acid, transferrin, dexametha-
sone, retinoic acid and TGF-3 for up to 46 days. The ex-
pression of type I, II, and X collagens, and some other 
components of chondrocyte matrix such as decorin, galectin-
1 and chitinase confirmed the acquisition of chondrocyte 
phenotype [38].  
 A comparative study carried out by Wang et al., high-
lighted the ability to differentiate in chondrocyte-like cells 
on poly-glycolic acid scaffold (PGA) in presence of chon-
drogenic medium for 6 week by WJ-MSCs and BM-MSCs. 
The authors observed that WJ-MSCs produced more GAGs 
and type I collagen than BM-MSCs [39]. A further study 
confirmed that WJ-MSCs cultured in a chondrogenic me-
dium on PGA scaffold, for 4 weeks, expressed GAGs and 
type I and II [40].  
 Recently, it was suggested that WJ-MSCs may differen-
tiate to chondrocyte-like cells if cultured on nanofibrous sub-
strates with a sequential two-steps culture, and differentiated 
cells expressed GAGs, hyaluronic acid, and some key genes 
for chondrocyte differentiation process such as SOX9, 
COMP (cartilage oligomeric matrix protein), collagen type II 
[41].  
Immunomodulatory Properties and Tolerogenic Activity 
by MSCs 
 Several reports described the expression of immuno-
modulatory molecules by MSCs and in particular by WJ-
MSCs. These data boosted the investigations on the possible 
interactions between MSC and immune response cells. 
 The mechanisms underlying immunomodulation by 
MSCs are different: suppression of T cell proliferation and 
dendritic cell differentiation [42], inhibition of B-cells [43], 
and natural killer cells (NK) proliferation [44], induction of 
T cells anergy and stimulation of regulatory T cells 
(CD4+CD25+FoxP3+ T regs) [45, 46]. 
 MSCs can modulate the immune system response by 
cytokines, growth factors, as well as the lack of co-
stimulatory molecules [47]. Release of soluble factors, such 
as IL-10 (interleukin-10), HLA-G, tumor necrosis factor 
alpha (TNF-), TGF-, is normally a results of cross-talk 
between MSCs and T-lymphocytes [48]. In particular, some 
reports demonstrated that HLA-G and its soluble form 
(HLA-G5), were expressed in BM-MSCs and WJ-MSCs [35, 
47, 49]. Other molecules belonging to non-canonical type I 
MHC where investigated by our group, on WJ-MSCs: HLA-
E and HLA-F. They are involved in the tolerance process 
between mother and fetus, and in particular HLA-E plays a 
key role during selective binding with NK cells [50, 51]. In 
addition, we recently demonstrated the expression of CD68 
in WJ-MSCs [52]. 
 A recent report, carried out by Spaggiari and co-workers, 
showed that MSCs are able to inhibit the NK cells prolifera-
tion, cytotoxicity and cytokine production, by down-
regulating the expression of activating NK receptors such as 
NKp30, NKp44, and NKG2D. This study demonstrated that 
possible mediators released by MSCs and involved in the 
inhibition of some NK- cells activities could be prostaglan-
din-E2 (PGE2) and indoleamine 2,3 dioxigenase (IDO) [44]. 
According to other works, PGE2, released by MSCs of dif-
ferent origin, can also modulate the activation and prolifera-
tion of lymphocyte subset [53].  
 Recently, some researchers suggested that molecules 
belonging to the B7 family, with a known co-stimulatory 
role, may have co-inhibitory role in the T-lymphocytes pro-
liferation. Some reports showed that B7-H3 (CD276), a co-
stimulatory molecule, inhibits human T cell activation, by 
decreasing the expression of interleukin-2 (IL-2) [54]. 
 CD80 (B7-1) and CD86 (B7-2) are other two co-
stimulatory molecules of T cells proliferation, but Sansom 
and co-workers highlighted that (in absence of CD86), the 
CD80 mostly exercises an inhibitory effect through binding 
of CD152 [55]. In conclusion, all these data supported the 
idea that MSCs could induce immune tolerance in the host. 
The main aim of the present work was the investigation of 
the maintenance of expression of immunomodulatory mole-
cules by WJ-MSCs before and after differentiation. 
MATERIALS AND METHODS 
Cellular Isolation Protocol of Wharton’s Jelly Mesen-
chymal Stem Cells 
 Isolation protocol was adopted from our previously pub-
lished data [35, 56]. All umbilical cords were obtained after 
mother’s informed consent according to tenets of the Decla-
ration of Helsinki and local ethical regulation. After normal 
vaginal or caesarean delivery, after full-term birth, umbilical 
cords were stored aseptically in cold saline and cellular isola-
tion was started within six hours from partum. The cords 
were washed in warm HBSS (Gibco), and then were cut in 
small pieces about 1.5 cm length, sectioned longitudinally so 
that to exhibit the Wharton’s jelly under amniotic epithe-
lium. Different incisions, without vessels removal, were 
made within matrix with sterile scalpel to increase area ex-
posed to the contact with medium composed by DMEM low 
glucose (Sigma), supplemented with 10% FBS (fetal bovine 
serum gold, PAA), 1x NEAA (non-essential aminoacids, 
Sigma), 1x antibiotics-antimycotics (GIBCO), and 2mM L-
glutamine (Sigma). This isolation protocol does not use en-
zymatic activity to dissociate cells from the embedding ma-
trix but is based on cells migratory ability. Cord pieces were 
left for 15 days with medium changed every second day. 
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Therefore, the slow degradation of the matrix allowed 
growth factors and signalling molecules to exit from the cord 
and continuing provide a positive stimulation to the cultured 
cells. 
 After 15 days of culture, cells widely adhered to the plas-
tic surface, and were cultured until confluence. 
Cell Culturing and Passaging 
 After reaching confluence, cells were removed from 
flasks with Tryple Select (Invitrogen) and were cultured for 
up to 15 passages. For immunocytochemical analysis, cells 
were plated in 8-well chamber slides (BD Bioscience) and 
were used after reaching 90% confluence. For RNA extrac-
tion, cells were cultured either in 6-well tissue culture plates 
or in 25cm2 tissue culture flasks (Corning). 
Immunohistochemistry 
 De-paraffinized sections, were washed with PBS-CaCl2, 
followed by addition of 0,3% hydrogen peroxide to inacti-
vate endogenous peroxidases. After 20 minutes in a blocking 
solution (1% of bovine serum albumin), they were incubated 
with specific primary antibodies for 1 hour and 30 minutes at 
room temperature. After another wash with PBS-CaCl2, sec-
tions were incubated with species-specific secondary anti-
bodies for 10 minutes. Subsequently, streptavidin-peroxidase 
(DAKO-Cytomation) was added followed by 3.3’-
diaminobenzidine (DAB chromogenic substrate solution, 
DAKO). At the end, haematoxylin (DAKO) was used to 
counter stain the nuclei of the cells.  
 The antibodies used in the present study, with indications 
of the working conditions used, are listed in Table 1. 
Total RNA Extraction 
 Total RNA extraction from Wharton’s jelly MSCs was 
made by RNAspin mini RNA isolation Kit (GE Healthcare), 
following the manufacturer’s instructions. 
 The RNA extract was stored at -20°C until use. The con-
centration of RNA extracted was determined by spectropho-
tometer with a wavelength of 260nm. Only samples with 
A260/A280 ratio over 1.7 were considered useful for the fol-
lowing analyses [57]. 
RT-PCR (Reverse Transcription Polymerase Chain Re-
action) 
 Qualitative RT-PCR was performed using Phusion High-
Fidelity RT-PCR kit (Finnzymes). The reaction comprised a 
reverse transcription step of 50 minutes at 42 C° and an inac-
tivation phase of 5 minute at 92 C°. The an amplification 
reaction was performed in a five steps: an initial denaturation 
of 30 seconds at 98C°, followed by another denaturation step 
of 10 seconds at 98 C°, the annealing phases of 30 seconds 
an extension step of 30 seconds at 72C°, and final extension 
for 10 minutes at 72 C°. See Table 2 for the list of primers 
used in this study. 
Osteogenic Differentiation 
 Differentiation of cells was performed by culturing WJ-
MSC at different passages in osteogenic differentiation me-
dium, mainly based on previous reports [35]. Briefly, culture 
medium was supplemented with 50 μM ascorbate-2-
phosphate (Sigma), 10 mM -glycerophosphate (Sigma), 0.1 
SM dexamethasone (Sigma), 10% FCS (PAA), 1x NEAA 
(non-essential aminoacids) (Sigma) and 1% antibi-
otic/antimycotic (Sigma). Cells were cultured in six-well 
tissue culture plates for 3 weeks and medium was replaced 
every second day. The formation of cell clusters resembling 
direct ossification was monitored by phase-contrast micros-
copy along culturing. Controls included WJ-MSCs cultured 
in normal growth medium for 3 weeks to monitor the even-
tual spontaneous formation of bone-like nodules.  
Adipogenic Differentiation 
 Differentiation of cells was performed by culturing WJ-
MSCs at different passages in adipogenic differentiation 
medium, mainly based on previous reports [35]: culture me-
Table 1.  List of antibodies used in the present study. 
Antigen Host Manufacturer Diluition 
B7-1 Mouse Santa Cruz 1:50 
B7-2 Mouse Santa Cruz 1:200 
B7-H3 Rabbit Santa Cruz 1:100 
Collagen II Mouse Merck Millipore 1:50 
CD31 Mouse Santa Cruz 1:50 
HLA-ABC Mouse Santa Cruz 1:50 
HLA-DR Mouse Santa Cruz 1:50 
HLA-E Mouse Santa Cruz 1:50 
IDO Mouse Santa Cruz 1:50 
Vimentin Mouse Santa Cruz 1:100 
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dium was supplemented with 0.5 mM isobutylmethylxan-
thine (Sigma),1 M dexamethasone (Sigma), 10 M insulin 
(Sigma), 200 M indomethacin (Sigma), 10% FBS (PAA), 
1x NEAA (non-essential aminoacids) (Sigma) and 1% anti-
biotic-antimycotic (Sigma). 
 Cells were cultured in six-well tissue culture plates for 3 
weeks, and medium was replaced every second day. The 
formation of cytoplasmic lipid vacuoles was monitored by 
phase-contrast microscopy along culturing. Controls in-
cluded W-MSCs cultured in standard growth medium for 3 
weeks to monitor the spontaneous formation of lipid vacu-
oles. 
Chondrogenic Differentiation 
 Differentiation of cells was performed by seeding WJ-
MSCs into alginate beads, using slight modifications of pre-
viously published protocols [58, 59]. Briefly, WJ-MSCs 
were resuspended in sodium alginate (Sigma-Aldrich)  
(4 x 106 cells/ml at a final concentration of 1,2% sodium 
alginate in sterile physiologic solution). Beads were formed 
by slowly dispensing droplets of the alginate cell suspension 
from a 22-gauge needle syringe into a 100 mM CaCl2 solu-
tion. After washes with 0.15 M NaCl, the beads were rinsed 
with DMEM. Then, beads were cultured either in standard 
growth medium (controls) or chondrogenic medium, pre-
pared using published protocols with slight modifications 
(DMEM supplemented with 1% FBS, 6.25 g/ml insulin, 10 
ng/ml TGF1, 50nM ascorbate-2-phosphate, 1% antibi-
otic/antimycotic, 1x NEAA) [36]. Beads were maintained in 
culture for three weeks, with medium changes every second 
day. For fixation and paraffin embedding, beads were proc-
essed as previously described [58, 59]. The beads were fixed 
in 4% paraformaldehyde, 0.1 M cacodylate buffer, pH 7.4, 
with 10 mM CaCl2 for 4 hrs at 20°C. and then washed over-
night at 4°C in 0.1 M cacodylate buffer (pH 7.4) containing 
50 mM BaCl2. The beads were standard dehydrated through 
alcohols and xylene and embedded in paraffin. Sections 
(6μm) were processed for histology (Alcian Blue and nuclear 
fast red staining) and IHC. 
Histochemical Staining 
 To demonstrate the acquisition of the osteogenic pheno-
type, the Alizarin Red S staining was performed. Briefly, 
cells were fixed in 4% paraformaldehyde and stained with 
1% solution of Alizarin Red S (Sigma). Stained cells were 
rinsed with water for three times to remove excess stain, and 
then photographed at the photomicroscope. 
 To demonstrate the adipogenic differentiation, cells were 
stained with Oil Red O (Sigma), and photographed at the 
photomicroscope. After medium aspiration, a brief wash was 
performed with PBS. Cells were fixed with 10% formalin 
(Sigma) for 30 min at room temperature, followed by subse-
quent washes with distilled water and 60% isopropanol. Oil 
Red O working solution was added to the cells for 5 min, 
followed by four washes (5 min each) with distilled water. 
The wells were viewed and photographed using an inverted 
phase-contrast microscope. Following a further step of coun-
terstaining (Meyer’s haematoxylin, 1 minute), lipid vacuoles 
appeared red and nuclei appeared blue. To demonstrate the 
acquisition of the chondrogenic phenotype, the alcian blue 
with nuclear fast red staining was performed. Cells cultured 
in alginate beads were formalin-fixed and paraffin embedded 
using standard protocols. Sections were de-paraffinized and 
hydrated to distilled water, then Alcian Blue (Sigma-
Aldrich) solution (1% Alcian Blue 8GX in 3% acetic acid, 
pH 2.5) was added for 30 minutes. After washing, nuclei 
were counterstained with nuclear fast red (Sigma-Aldrich) 
Table 2. List of PCR primers used for the present study. 
Name Accession 
number 
Product 
Size 
Forward Primer Reverse Primer 
Actin, beta NM_001101 350 5’-AAACTGGAACGGTGAAGGTG-3’ 5’-TCAAGTTGGGGGACAAAAAG-3’ 
B7-H1 NM_014143 271 5’-GGTCTGGGACGGTTGGATA-3’ 5’-CCCATGGGATCTTTTGAATTT-3’ 
B7-H3 NM_025240 170 5-CCCTCCCTACAGCTCCTACC-3 5-CAGCAGGATGACTTGGGAAT-3 
B7-H4 NM_024626 273 5’-CAGGGAGACACTCCATCACA-3’ 5’-TGAGTTGCACGTTTTTCAGC-3’ 
CD80 NM_005191 259 5’-AGGGCCTCCTTAGATCCCTA-3’ 5’-TTAGCTGCCATGAGATGTGC-3’ 
CD86 NM_175862 250 5’-TCCTGGCTGAGAGAGGAAGA-3’ 5’-AGACTGCCCCATCCCTTAGT-3’ 
HLA-A NM_002116 262 5’-TGGGACTGAGAGGCAAGAGT-3’ 5’-ACAGCTCAGTGCACCATGAA-3’ 
HLA-DR-B1 NM_002124 349 5’-GCACAGAGCAAGATGCTGAG-3’ 5’-AGTTGAAGATGAGGCGCTGT-3’ 
HLA-E NM_005516 245 5’-CAAGGGCCTCTGAATCTGTC-3’ 5’-CGTGTTAGCCAGGATGGTTT-3’ 
HLA-G NM_002127 287 5-GCTCCCACTCCATGAGGTATT-3 5- CTGGAGGGTGTGAGAACTGG-3 
HLA-F 
NM_00109847
9 
202 5’-TGGAGTTGCTCCGCAGATA-3’ 5’-TCCACAAGCTCTGTGTCCTG-3’ 
TGF2 NM_003231 282 5’-TGCGGCCTATTGCTTTAGA-3’ 5’-TTGGGTGTTTTGCCAATGT-3’ 
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solution (0.1%). Sections were then dehydrated and mounted 
for observation (not shown). 
RESULTS 
Cellular Isolation of WJ-MSCs 
 The isolation protocol of WJ-MSCs which we developed 
allows to reproducibly isolate and expand plastic-adherent 
cells starting from tissue explants. During 15 days, WJ-
MSCs exit from samples and migrate to adhere to the sub-
strate, therefore the slow degradation of the matrix determine 
a continue stimulation for cells by growth factor and signal-
ling molecules action. WJ-MSCs cultured in standard growth 
medium showed fibroblastoid morphology at different con-
fluence states. As visible in Fig. (1) the typical mesenchymal 
morphology of WJ-MSCs isolated from different samples is 
maintained at different passages. 
 Confluent cells were routinely splitted and maintained in 
culture up to 15th passage, with a mean population doubling 
time of 7.5 days. To confirm the long-term storability and 
the ability to survive deep freezing, the cultured cells were 
freezed and stored in liquid nitrogen at different passages 
and subsequently were defrosted and cultured (data not 
shown). Standard immunocytochemical and molecular 
analyses were routinely performed on freshly isolated cells 
to assess the expression of typical mesenchymal markers and 
the absence of haematopoietic/endothelial markers (data not 
shown). 
Tri-Lineage Differentiation of WJ-MSCs 
 According to the general consensus, MSCs are consid-
ered multiopotent stem cells since they can be differentiated 
into almost three different cell types: osteocytes, adipocytes 
and chondroblasts. 
 For osteogenic differentiation, WJ-MSCs were cultured 
in a maturation medium for three weeks. For the same time, 
control cells were cultured in standard growth medium. The 
process of osteoblast differentiation was assessed by Alizarin 
Red S staining: as visible in Fig. (2A, B), control cells were 
negative to the staining, while the differentiated cells showed 
a red staining, indicating of the accumulation of extracellular 
calcium-containing deposits. Moreover, the control cells, 
cultured in a standard growth medium, maintained the fibro-
blastoid morphology, while the cells induced to osteogenic 
differentiation, showed the formation of cellular aggregates, 
similar to bone nodules. 
 To demonstrate that WJ-MSCs may differentate towards 
adipocyte-like cells, we cultured our cells in a medium sup-
plemented with adipogenic inducers and in a control medium 
for three weeks. By phase-contrast microscopy, it possible to 
observe in Fig. (2C, D) the presence of multiple intracellular 
 
Fig. (1). Light microscopic micrographs of different WJ-MSCs populations in monolayer culture. Cultured cells assumed a polymorphic, 
fibrobroblast-like morphology, which was maintained throughout the passaging process. The panels show: cells at passage 1, prior to reach 
confluence (A); confluent cells at passage 1 (B); confluent monolayer at passage 1 (C, D). Magnification x20. Bar: 100μ. 
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vacuoles, only in differentiated cells, as demonstrated by Oil 
Red O staining, which allowed to highlight the presence of 
multiple neutral lipid vacuoles of different sizes in adipo-
cyte-like cells, resembling multivacuolar adipocytes of 
brown fat. As expected, control cells were negative to this 
staining. 
 For chondrogenic differentiation, we cultured cells, after 
seeding in alginate matrix, in presence of a medium supple-
mented with chondrogenic inducers and, for controls, in a 
standard growth medium for three weeks, as we reported 
previously [59]. As visible in Fig. (2F), only differentiated 
cells featured the expected formation of lacunae, while con-
trol cells do not (Fig. 2E). The acquisition of a chondrogenic 
phenotype was also confirmed by immunocytochemical 
analysis (see below), by evaluating the expression of type II 
collagen, which is characteristically expressed in cartilage.  
Expression of Immunomodulatory Molecules in Control 
and Chondrogenic-Like Cells, Cultured in Alginate Ma-
trix 
 Since one of the main features of MSCs is the immune 
modulation of lymphocyte activity in vitro and in vivo, the 
maintenance of these characteristics by differentiated cells 
clearly deserves further investigation. Few papers are present 
 
Fig. (2). Light microscopic demonstration of bone tissue formation by WJ-MSCs following osteogenic differentiation. WJ-MSCs cultured in 
osteogenic medium assume a cuboidal shape with formation and deposit of a mineralized matrix assessed by Alizarin Red S staining (B), 
with respect to fibroblastoid, staining-negative control cells (A). Adipogenic-like cells feature the presence of neutral lipid vacuoles, evi-
denced by Oil red staining (D), which are absent in control cells (C). WJ-MSCs cultured for 3 weeks in chondrogenic medium, in alginate 
matrix showed morphological variations (appearance of rounded lacunae, indicated by arrows) (F) with respect to control cells (E). Magnifi-
cation: x10 (A, B), x20 (C-F). Bar: 100μ. 
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in literature dealing with the immune features of differenti-
ated cells, with contrasting results between the osteogenic 
and chondrogenic model. In addition, the number of im-
mune-related molecules investigated remains low, often lim-
ited to the MHC molecules and classical B7 costimulators 
(CD80 and CD86). 
 Therefore, to extend the previous reports and try to eluci-
date whether the expression of immunomodulatory mole-
cules may be a feature only of undifferentiated WJ-MSCs, 
we evaluated the expression of different immune molecules 
also in differentiated cells and in particular in chondrogenic-
like cells. Immunohistochemistry analysis on alginate-
cultured cells confirmed the expression of type I MHC such 
(HLA-A-B-C) and the lack of HLA-DR, a type II MHC, 
both in undifferentiated and differentiated cells Fig. (3), pan-
els A-D). According to recent data in literature [56], also 
WJ-MSCs expressed HLA-E, a non-classical type I MHC 
molecule involved during tolerance-induction processes and 
in particular in the selective binding with NK cells. Even if 
WJ-MSCs do express HLA-E when cultured in standard 
conditions, as shown below for the osteogenic and adipo-
genic differentiation experiments, chondrogenic differentia-
tion shows that neither alginate-seeded undifferentiated cells, 
nor differentiated ones, did express this marker at the protein 
level. We may hypothesize that the three-dimensional algi-
nate matrix influences the cellular behaviour so that the ex-
pression of some factors is lost even in undifferentiated cells. 
 
Fig. (3). Representative panels of immunohistochemistry detection of immune-related molecules by WJ-MSCs cultured in alginate matrix 
and induced to differentiate in presence of chondrogenic medium. Control cells were cultured in a standard growth medium. HLA-A/B/C 
was expressed in both control (A) and chondrogenic-like cells (B), while HLA-DR was not detectable in any condition (C, D). Control cells 
showed positivity for B7-H3 (CD276) (E), with the light staining which was also present in differentiated cells (F). Magnification x 40 (A, 
B); x20 (C-F). Bar: 100μ. 
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In our opinion, further research is needed to better clarify 
this issue in the chondrogenic differentiation model. Another 
immunomodulatory molecule which has been demonstrated 
to be expressed by MSCs is IDO, an enzyme involved in the 
tryptophan metabolism, an essential aminoacid for lympho-
cyte proliferation (see Table 3). Also for this molecule, its 
expression in WJ-MSCs was demonstrated in our laboratory 
(Anzalone et al., manuscript in preparation). However, as 
observed for HLA-E, alginate embedding seems to block the 
expression of IDO at the protein level in both undifferenti-
ated and differentiated cells.  
 The expression of molecules belonging to the B7 super-
family is of critical importance for their role as costimulators 
in immune processes. MSCs are mainly negative for classi-
cal members of this family, as B7-1 (CD80) and B7-2 
(CD86). As shown in Table 3, both molecules were absent in 
both control and chondrogenic cells, therefore confirming 
the maintenance of the immune asset of these molecules af-
ter differentiation. In addition, for the first time in WJ-MSC, 
we demonstrated in both undifferentiated and chondrogenic-
like cells the presence of B7-H3 (CD276), (Fig. 3E, F). For 
this co-stimulatory molecule also co-inhibitory roles have 
been suggested [49]. Immunohistochemical detection al-
lowed to confirm the mesenchymal phenotype by these cells, 
highlighting the expression of vimentin, an intermediate 
filament found in cells of mesenchymal origin (Fig. 4C, D). 
To confirm the acquisition of chondrogenic phenotype by 
WJ-MSCs, we evaluated the expression of a cartilage-
specific protein, type II collagen, as shown in Fig. (4A,B). 
According general consensus MSCs population do not ex-
press haematopoietic stem cells markers, and here we 
showed the lack expression of CD31 both in undifferentiated 
and differentiated WJ-MSCs. (see Table 3). 
Expression of Immunomodulatory Molecules in Os-
teogenic and Adipogenic Control and Differentiated Cells  
 A further comparative analysis was carried out in parallel 
between WJ-MSCs and differentiated adipogenic and os-
teogenic-like cells by qualitative RT-PCR. 
 As shown in Table 4, WJ-MSCs differentiated towards 
osteogenic and adipogenic lineages do maintain the expres-
sion of some immune-related molecules compared to control 
cells. In fact, as also shown in Fig. (5), the non-classical type 
I MHC molecules HLA-E, HLA-F and HLA-G, are ex-
pressed in both control and differentiated cells. This consti-
tutes, to the best of our knowledge, the first evidence in 
MSC-derived differentiated cells. Both undifferentiated and 
differentiated cells the lacked the expression of HLA-DR as 
shown in Table 4 and in Fig. (5). HLA-F and HLA-G are 
two non canonical class Ib MHC molecules involved during 
the establishment of tolerance processes between mother and 
fetus. Molecular biology analysis further confirmed the ex-
pression of B7-H3 in both undifferentiated and differentiate 
cells. (see Table 4). Since other reports highlighted the pres-
 
Fig. (4). Immunohistochemical demonstration of collagen type II expression by chondrogenic-differentiated WJ-MSCs. Cells cultured in 
alginate matrix with standard growth medium did not form lacunae around cells, and did express both type II collagen (A) and vimentin (C). 
Alginate-seeded cells grown in differentiation medium showed the appearance of pericellular lacunae, and maintained the expression of both 
type II collagen (B) and, at a lesser extent, vimentin (D). Magnification: x20. Bar: 100μ. 
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ence in BM-MSCs of other molecules belonging to B7 fam-
ily, known to have also a co-inhibitory role, such as B7-H1 
and B7-H4, we wanted to assess their expression in WJ-
MSCs. As detailed in table 4, both undifferentiated and dif-
ferentiated cells do not express these molecules. 
 The presented data collectively demonstrate that WJ-
MSCs maintain the expression of immune-related molecules 
in both undifferentiated and differentiated state, therefore 
suggesting that these cells may be considered good candi-
dates for clinical applications. 
DISCUSSION 
 In the last years, musculoskeletal and arthritic disorders 
are increasingly viewed as one of the main causes of disabil-
ity in the world. OA and RA are now recognized, by World 
Health Organization, as the musculoskeletal conditions that 
induce major health troubles [60]. 
 Articular cartilage is the main target of these disorders 
which heavily affect its structure. Chondrocytes represent the 
only cellular type of cartilage. They are plunged in the ma-
trix and are fed thanks to diffusion processes due to the 
avascularity of this tissue. For this reason, the cartilage re-
generation and repair processes are very slow. Thanks to the 
differentiative capacity of mesenchymal stem cells, there is 
accumulating evidence for their use in cartilage tissue engi-
neering and musculoskeletal tissue regeneration [2]. Articu-
lar cartilage is avascular while bone is very well vascular-
ized: thanks to the presence of some capillaries in sub-
chondral bone at the cartilagine-bone interface, chondrocytes 
receive nutrients and can perform gas exchange. A recent 
work suggested the use of a vascularized tissue engineered 
construct obtained by presence of tissue progenitor and vas-
cular progenitor cells into biocompatible scaffold [61]. Par-
ticular interest was demonstrated in the use of specific media 
to support proliferation by MSCs and their trans-
differentiation process. Some studies showed that hypoxia 
can induce chondrogenesis and chondrogenic differentiation 
of MSCs [62-64]. Further reports highlighted the use of a 
bioreactor with co-culture of MSCs and other stem cells to 
study the culture and mechanical stimulation [65]. Emerging 
data showed that MSCs could modulate innate and adaptive 
immunity by several mechanisms, therefore reinforcing the 
concept of their use for cellular therapy. MSCs inhibit T-
Table 3. Immunohistochemistry results of markers expression by undifferentiated and chondrogenic-like cells. Results of the im-
munohistochemistry analysis are represented semiquantitatively. 
Antigen Control Differentiated 
B7-H3 ++ ++ 
B7-1 - - 
B7-2 - - 
      CD31           -            - 
Collagen II + ++ 
HLA-ABC ++ + 
HLA-DR - - 
HLA-E - - 
IDO - - 
Vimentin ++ + 
Table 4. RT-PCR results of immune molecules expression by control and differentiated cells (adipogenic-like cells and osteogenic-
like cells). Results of molecular analysis are represented qualitatively. 
Immune Molecules Control Cells Osteogenic-Like Cells Control Cells Adipocyte-Like Cells 
B7-H1 - - - - 
B7-H3 + + + + 
B7-H4 - - - - 
CD80 - - - - 
CD86 - - - - 
HLA-A + + + + 
HLA-DR - - - - 
HLA-E + + + + 
HLA-F + + + + 
HLA-G + + + + 
TGF2 + + + + 
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lymphocyte proliferation and activation by soluble factors 
such as TGF- PGE2, HGF and IDO [66]. In particular, 
MSCs could decrease IFN- production and could increase 
the IL-4 expression, determining a switch from pro-
inflammatory state to anti-inflammatory one [67].  
 In the present paper, we aimed to determine the expres-
sion, both in undifferentiated and differentiated cells, of 
some of the major immune-related molecules which have 
been suggested as responsible of MSCs immune privilege. 
 T- cell anergy is mechanism by which MSCs induce im-
munosuppression: some authors demonstrated that the lack 
expression of two co-stimulatory molecules such as CD80 
(B7-1) and CD86 (B7-2) by MSCs could induce an anergy 
state in T cells [68]. In our report, we showed by immuno-
histochemistry analysis that both undifferentiated and differ-
entiated WJ-MSCs do not express the two B7 molecules. 
Recent reports indicated that other members of the B7-
family, namely B7-H1, B7-H3, B7-H4 may have promising 
co-inhibitory roles in addition to known co-stimulatory roles. 
Previously, the expression of B7-H1 and B7-H4 has been 
demonstrated in BM-MSCs [50]. In contrast, our results 
showed the lack expression of these two molecules in both 
undifferentiated and differentiated WJ-MSCs. On the con-
trary, we demonstrated that our cells do express B7-H3 
(CD276) at both the protein and RNA level. The expression 
of such marker seems to be unaffected by the differentiation 
protocol applied, and recalls what we just observed in human 
heart-derived MSCs, which are the first class of adult MSCs 
in which CD276 expression has been characterized [59]. 
 Classical and non-classical class I MHC molecules are 
increasingly being considered as promising molecules for the 
global immune privilege of mesenchymal stem cells. In lit-
erature, some reports highlighted the capacity by MSCs to 
determine a tolerance process by inducing the proliferation 
of regulatory T cells (T regs) by release of the HLA-G iso-
form HLA-G5. In our experiments, RT-PCR analysis al-
lowed to highlight the expression of HLA-G mRNA in con-
trol cells and osteogenic and adipogenic differentiated cells. 
Other class Ib MHC molecules are HLA-E and HLA-F, pro-
duced by trophoblast cells together with EPF (early preg-
nancy factor) [69]. All these molecules have been involved 
in the tolerance process between mother and fetus. The ex-
pression of these molecules in MSCs has been highlighted in 
heart-derived MSCs [59], and we wanted to better detail 
their presence also in WJ-MSCs. We demonstrated by RT-
PCR analysis that WJ-MSCs express both these class Ib 
MHC, in both undifferentiated and differentiated state. This 
is the first report highlighting the expression of HLA-F in 
WJ-MSCs. 
 Collectively, these data may provide a further point in the 
characterization of differentiated cells not only on the basis 
of the expression of desired markers of the mature cytotype, 
Fig. (5). Representative panels of RT-PCR analysis of immune molecules expression in WJ-MSC subjected to adipogenic or osteogenic dif-
ferentiation. WJ-MSC cultured for three weeks in presence of osteogenic and adipogenic medium showed the expression of HLA-A and 
HLA-E, while HLA-DR was not detectable. Control WJ-MSC cultured for three weeks in a standard growth medium show the same pattern 
of immune molecules expression. M: 50 bp ladder. Left lanes are referred to controls and right lane sto differentiated cells, for any molecole 
considered. 
Human Wharton's Jelly Mesenchymal Stem Cells Current Stem Cell Research & Therapy, 2013, Vol. 8, No. 1    111 
but also for the maintenance of the immunomodulatory 
properties of naïve cells, which may further promote the re-
parative action of these cells if used in regenerative medicine 
applications. A number of diseases which in their final stages 
require organ transplant or cellular therapy, derive from or 
are accompanied by, an unbalance in the organ inflammatory 
or immune state. To this regard, the use of a cellular therapy 
vehicle which may provide both organ recellularization and 
restoration of a physiological microenvironment, may be a 
further benefit for patients. In addition, as MSCs are globally 
recognized for their immune privilege, which allows to 
evade the host immune response also in allogeneic settings, 
the possibility that also differentiated cells may maintain this 
feature deserves further research and in vivo applications for 
the increasing potential beneficial outcomes it can reserve. 
Literature reports did suggest that the chondrogenic differen-
tiation process often fails in maintaining the immunomodula-
tory features of undifferentiated cells, when compared to the 
adipogenic or osteogenic differentiations [70-72]. Our pre-
sent data suggest that for some antigens (as HLA-E), the 
alginate-embedding protocol may result in a phenotypycal 
switch also in the control cells. However, the positive corre-
lation observed for the other MHC molecules, and the B7 
costimulators monitored, strongly point to the maintenance 
of immune-related molecules as a global feature of differen-
tiated WJ-MSCs.  
REFERENCE 
 Our data strongly support the concept of WJ-MSCs as a 
reliable and promising option for cellular therapy, in the 
regenerative and reparative medicine field.  
CONFLICT OF INTEREST 
 Dr. La Rocca is member of the Scientific Board of 
Auxocell Laboratories, Inc. The funders had no role in article 
design, data collection, decision to publish, or preparation of 
the manuscript. 
ACKNOWLEDGEMENTS 
 Authors’ results referred to in this paper were in part 
supported by University of Palermo grants (ex 60% 2007) to 
RA, FF, GLR and Istituto Euro-Mediterraneo di Scienza e 
Tecnologia (IEMEST) to GLR. 
REFERENCES 
[1] Lo Iacono M, Anzalone R, Corrao S, et al. Perinatal and Wharton’s 
Jelly-derived mesenchymal stem cells in cartilage regenerative 
medicine and tissue engineering strategies. Open Tissue Eng Regen 
Med J 2011; 4:72-81 
[2] Mobasheri A, Shakibaei M. Applications of mesenchymal stem 
cells in cartilage tissue engineering-part 1. Recent Pat Regen Med 
2011; 1: 30-41. 
[3] Buckwalter JA, Mankin HJ. Articular cartilage: Tissue design and 
chondrocyte-matrix interactions. Instr Course Lect 1998; 47: 477-
86 
[4] Kuettner KE, Aydelotte MB, Thonar EJ. Articular cartilage matrix 
and structure: A minireview. J Rheumatol Suppl 1991; 27: 46-8 
[5] Ogawa R. Recent patents on stem cell-mediated cartilage regenera-
tion and repair. Recent Pat Regen Med 2011; 1: 118-22 
[6] Buckwalter JA, Mankin HJ. Articular cartilage repair and trans-
plantation. Arthritis Rheum 1998; 41: 1331-42. 
[7] Kim AJ, Adkisson HD, Wendland M, et al. Juvenile chondrocytes 
may facilitate disc repair. Open Tissue Eng Regen Med J 2010; 3: 
28-35. 
[8] Barna M, Niswander L. Visualization of cartilage formation: in-
sight into cellular properties of skeletal progenitors and chondro-
dysplasia syndromes. Dev Cell 2007; 12: 931-41. 
[9] Ng LJ, Tam PP, Cheah, KS. Preferential expression of alternatively 
spliced mRNAs encoding type II procollagen with a cysteine-rich 
amino-propeptide in differentiating cartilage and nonchondrogenic 
tissues during early mouse development. Dev Biol 1993; 159: 403-
17. 
[10] Sandell LJ, Morris N, Robbins JR, Goldring MB. Alternatively 
spliced type II procollagen mRNAs define distinct populations of 
cells during vertebral development: differential expression of the 
amino-propeptide. J Cell Biol 1991; 114: 1307-19. 
[11] Oberlender SA, Tuan RS. Expression and functional involvement 
of N-cadheri in embryonic limb chondrogenesis. Development 
1994; 120: 177-87. 
[12] Widelitz RB, Jiang TX, Murray BA, Chuong CM. Adhesion mole-
cules in skeletogenesis: II. Neural cell adhesion molecules mediate 
precartilaginous mesenchymal condensations and enhance chon-
drogenesis. J Cell Physiol 1993; 156: 399-411. 
[13] Mackie EJ, Thesleff I, Chiquet-Ehrismann R. Tenascin is associ-
ated with chondrogenic and osteogenic differentiation in vivo and 
promotes chondrogenesis in vitro. J Cell Biol 1987; 105: 2569-79. 
[14] Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crom-
brugghe B. The transcription factor Sox9 has essential roles in suc-
cessive steps of the chondrocyte differentiation pathway and is re-
quired for expression of Sox5 and Sox6. Genes Dev 2002; 16: 
2813-28. 
[15] Zuscik J, Hilton MJ, Zhang X, Chen D, O’Keefe RJ. Regulation of 
chondrogenesis and chondrocyte differentiation by stress. J Clin 
Invest 2008; 118: 429-38  
[16] Sandell LJ, Morris N, Robbins JR, Goldring MB. Alternatively 
spliced type II procollagen mRNAs define distinct populations of 
cells during vertebral development: differential expression of the 
amino-propeptide. J Cell Biol 1991; 114: 1307-19 
[17] Bobick BE, Chen FH, Le AM, Tuan RS. Regulation of the chon-
drogenic phenotype in culture. Birth Defects Res C Embryo Today 
2009; 87:351-71 
[18] Freyria AM, Mallein-Gerin F. Chondrocytes or adult stem cells for 
cartilage repair: The indisputable role of growth factors. Injury 
2012; 43: 259-65. 
[19] Gouttenoire J, Bougault C, Aubert-Foucher E, et al. BMP-2 and 
TGF-beta1 differentially control expression of type II procollagen 
and alpha 10 and alpha 11 integrins in mouse chondrocytes. Eur J 
Cell Biol 2010; 89: 307-14. 
[20] Valcourt U, Gouttenoire J, Aubert-Foucher E, et al. Alternative 
splicing of type II procollagen pre-mRNA in chondrocytes is oppo-
sitely regulated by BMP-2 and TGF-beta1. FEBS Lett 2003; 545: 
115-9. 
[21] Hautier A, Salentey V, Aubert-Foucher E, et al. Bone morphoge-
netic protein-2 stimulates chondrogenic expression in human nasal 
chondrocytes expanded in vitro. Growth Factors 2008; 26: 201-11. 
[22] Hui TY, Cheung KM, Cheung WL, et al. In vitro chondrogenic 
differentiation of human mesenchymal stem cells in collagen mi-
crospheres: influence of cell seeding density and collagen concen-
tration. Biomaterials 2008; 29: 3201-12. 
[23] Noth U, Rackwitz L, Heymer A, et al. Chondrogenic differentia-
tion of human mesenchymal stem cells in collagen type I hydro-
gels. J Biomed Mater Res A 2007; 83:626-35 
[24] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential 
of adult human mesenchymal stem cells. Science 1999; 284: 143-7. 
[25] Shen B, Wei A, Tao H, et al. BMP-2 enhances TGF-beta3-
mediated chondrogenic differentiation of human bone marrow mul-
tipotent mesenchymal stromal cells in alginate bead culture. Tissue 
Eng Part A 2009; 15: 1311-20. 
[26] Kavalkovich KW, Boynton RE, Murphy MJ, Barry F. Chondro-
genic differentiation of human mesenchymal stem cells within an 
alginate layer culture system. In vitro Cell and Dev Biol-Animal 
2002; 38: 457-66. 
112    Current Stem Cell Research & Therapy, 2013, Vol. 8, No. 1 La Rocca et al. 
[27] Guo JF, Jourdian GW, MacCallum DK. Culture and growth charac-
teristics of chondrocytes encapsulated in alginate beads. Connect 
Tissue Res 1989; 19(suppl. 2-4): 277-97. 
[28] Friedenstein AJ, Gorskaya JF, Kulagina NN. Fibroblast precursors 
in normal and irradiated mouse hematopoietic organs. Experimen-
tal Hematology 1976; 4: 267-74. 
[29] Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, An-
nunziato F. Regenerative and immunomodulatory potential of mes-
enchymal stem cells. Curr Opin Pharmacol 2006; 6: 435-41 
[30] Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji 
K. Human placenta derived cells have mesenchymal stem/ progeni-
tor cell potential. Stem Cells 2004; 22: 649-58 
[31] Rao MS, Mattson MP. Stem cells and aging: Expanding the possi-
bilities. Mech Aging Dev 2001; 122: 713-34. 
[32] Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton's Jelly stem 
cells: future clinical applications. Placenta 2011; 32 Suppl 4: S311-
5. 
[33] La Rocca G, Di Stefano A, Eleuteri E, et al. Oxidative stress in-
duces myeloperoxidase expression in endocardial endothelial cells 
from patients with chronic heart failure. Basic Res Cardiol 2009; 
104: 307-20. 
[34] Anzalone R, La Rocca G, Di Stefano A, et al. Role of endothelial 
cell stress in the pathogenesis of chronic heart failure. Front Biosci 
2009; 14: 2238-47. 
[35] La Rocca G, Anzalone R, Corrao S, et al. Isolation and 
characterization of Oct-4+/HLA-G+ mesenchymal stem cells from 
human umbilical cord matrix: differentiation potential and 
detection of new markers. Histochem Cell Biol 2009; 131: 267-282 
[36] Can A, Karahuseyinoglu S. Human umbilical cord stroma with 
regard to the Source of foetus-derived stem cells. Stem Cells 2007; 
25: 2886-95. 
[37] La Rocca G. Connecting the dots: the promises of Wharton's jelly 
mesenchymal stem cells for tissue repair and regeneration. Open 
Tissue Eng Regen Med J 2011; 4: 3-5. 
[38] Arufe MC, De la Fuente A, Mateos J, et al. Analysis of the chon-
drogenic potential and secretome of mesenchymal stem cells de-
rived from human umbilical cord stroma. Stem Cells Dev 2011; 20: 
1199-212. 
[39] Wang L, Tran I, Seshareddy K, Weiss ML, Detamore MS. A com-
parison of human bone marrow–derived mesenchymal stem cells 
and human umbilical cord–derived mesenchymal stromal cells for 
cartilage tissue engineering. Tissue Eng Part A 2009; 15: 2259-66. 
[40] Wang L, Seshareddy K, Weiss ML, Detamore MS. Effect of initial 
seeding density on human umbilical cord mesenchymal stromal 
Cells for fibrocartilage tissue engineering. Tissue Eng Part A 2009; 
15: 1009-17. 
[41] Fong C-Y, Subramanian A, Gauthaman K, et al. Human umbilical 
cord Wharton’s jelly stem cells undergo enhanced chondrogenic 
differentiation when grown on nanofibrous scaffolds and in a se-
quential two-stage culture medium environment. Stem Cell Rev 
Rep 2012; 8: 195-209. 
[42] Vija L, Fargec, D, Gautier JF, et al. Mesenchymal stem cells: stem 
cell therapy perspectives for type 1 diabetes. Diabetes Metab 2009; 
35: 85-93. 
[43] Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal 
stem cells modulate B-cell functions. Blood 2006; 107: 367-372. 
[44] Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari 
MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell 
proliferation, cytotoxicity, and cytokine production: role of in-
doleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 
111: 1327-33.  
[45] Li DS, Warnock GL, Tu HJ, et al. Do immunotherapy and  cell 
replacement play a sinergistic role in the treatment of type 1 diabe-
tes? Life Sciences 2009; 85: 549-56. 
[46] Nichols J, Cooke A. Overcoming self-destruction in pancreas. Curr 
Opin Biotechnol 2009; 20: 511-15. 
[47] Weiss ML, Anderson C, Medicetty S, et al. Immune properties of 
human umbilical cord Wharton’s jelly-derived cells. Stem Cells 
2008; 26: 2865-74.  
[48] Alma J, Nauta W, Fibbe E. Immunomodulatory properties of mes-
enchymal stromal cells. Blood 2007; 110: 3499-506. 
[49] Selmani Z, Naji A, Gaiffe E, et al. HLA-G is a crucial immunosup-
pressive molecule secreted by adult human mesenchymal stem 
cells. Transplantation 2009; 87(9 Suppl.): S62-S66. 
[50] Anzalone R, Lo Iacono M, Loria T, et al. Wharton's jelly mesen-
chymal stem cells as candidates for beta cells regeneration: Extend-
ing the differentiative and immunomodulatory benefits of adult 
mesenchymal stem cells for the treatment of type 1 diabetes. Stem 
Cell Rev Rep 2011; 7: 342-63. 
[51] Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for 
the natural killer inhibitory receptor CD94yNKG2A. Proc Natl 
Acad Sci USA 1998; 95: 5199-204. 
[52] La Rocca G, Anzalone R, Farina F. The expression of CD68 in 
human umbilical cord mesenchymal stem cells: new evidences of 
presence in non-myeloid cell types. Scand J Immunol 2009; 70 (2): 
161-2. 
[53] Najar M, Raicevic G, Boufker HI, et al. Mesenchymal stromal cells 
use PGE2 to modulate activation and proliferation of lymphocyte 
subsets: combined comparison of adipose tissue, Wharton’s Jelly 
and bone marrow sources. Cell Immunol 2010; 264: 171-9. 
[54] Leitner J, Klause C, Pickl WF, et al. B7-H3 is a potent inhibitor of 
human T-cell activation: No evidence for B7-H3 and TREML2 in-
teraction. Eur. J. Immunol. 2009; 39: 1754-64 
[55] Sansom DM, Manzotti CN, Zheng Y. What’s the difference be-
tween CD80 and CD86? Trends Immunol 2003; 24: 313-8. 
[56] Anzalone R, Farina F, Zummo G, La Rocca G. Recent patents and 
advances on isolation and cellular therapy applications of mesen-
chymal stem cells from human umbilical cord Wharton's jelly. Re-
cent Pat Regen Med 2011; 1: 216-27. 
[57] La Rocca G, Anzalone R, Magno F, Farina F, Cappello F, Zummo 
G. Cigarette smoke exposure inhibits extracellular MMP-2 (gelati-
nose A) activity in human lung fibroblasts. Resp Res 2007; 8: 23. 
[58] Petit B, Masuda K, D’Souza A, et al. Characterization of 
crosslinked collagens synthesized by mature articular chondrocytes 
cultured in alginate beads: comparison of two distinct matrix com-
partments. Experimental Cell Research 1996; 225: 151-61. 
[59] Anzalone R, Corrao S, Lo Iacono M, et al. Isolation and Charac-
terization of CD276+/HLA-E+ Human Subendocardial Mesen-
chymal Stem Cells from Chronic Heart Failure Patients: Analysis 
of Differentiative Potential and Immunomodulatory Markers Ex-
pression.Stem Cells Dev 2013; 22: 1-17. 
[60] Walsh NE, Brooks P, Hazes JM, et al. Standards of care for acute 
and chronic musculoskeletal pain: The bone and joint decade 
(2000-2010). Arch Phys Med Rehabil 2008; 89: 1830-45. 
[61] Mao, JJ. De novo formation and regeneration of vascularized tissue 
from tissue progenitor cells and vascular progenitor cells. 
US20100136114 (2010). 
[62] Ronziere MC, Perrier E, Mallein-Gerin F, Freyria AM. Chondro-
genic potential of bone marrow- and adipose tissuederived adult 
human mesenchymal stem cells. Biomed Mater Eng 2010; 20: 145-
58. 
[63] Baumgartner L, Arnhold S, Brixius K, Addicks K, Bloch W. Hu-
man mesenchymal stem cells: Influence of oxygen pressure on pro-
liferation and chondrogenic differentiation in fibrin glue in vitro. J 
Biomed Mater Res A 2010; 93: 930-40. 
[64] Lafont JE. Lack of oxygen in articular cartilage: consequences for 
chondrocyte biology. Int J Exp Pathol 2010; 91: 99-106 
[65] Duda GN, Petersen A. New components and new bioreactor system 
for the culture and mechanical stimulation of biological material. 
EP2184347 (2009). 
[66] Anzalone R, Lo Iacono M, Corrao S, et al. New emerging poten-
tials for human Wharton’s jelly mesenchymal stem cells: immu-
nological features and hepatocyte-like differentiative capacity. 
Stem Cell Dev 2010; 19: 423-38 
[67] Aggarwal S, Pittenger MF. Human mesenchymal stem cells modu-
late allogeneic immune cell responses. Blood 2005; 105: 1815-22. 
[68] La Rocca G, Corrao S, Lo Iacono M, Corsello T, Farina F, An-
zalone R. Novel Immunomodulatory markers espressed by human 
WJ-MSC: an update review in regenerative and reparative medi-
cine. Open Tissue Eng Regen Med J 2012; 5: 50-8. 
[69] Corrao S, Campanella C, Anzalone R, et al. Human Hsp10 and 
Early Pregnancy Factor (EPF) and their relationship and involve-
ment in cancer and immunity: current knowledge and perspectives. 
Life Sci 2010; 86: 145-52. 
Human Wharton's Jelly Mesenchymal Stem Cells Current Stem Cell Research & Therapy, 2013, Vol. 8, No. 1    113 
[70] Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ, Cao T. 
The immunogenicity and immunomodulatory function of os-
teogenic cells differentiated from mesenchymal stem cells. J Im-
munol 2006; 176: 2864-71. 
[71] Zheng ZH, Li XY, Ding J, Jia JF, Zhu P. Allogeneic mesenchymal 
stem cell and mesenchymal stem cell-differentiated chondrocyte 
suppress the responses of type II collagen-reactive T cells in rheu-
matoid arthritis. Rheumatology 2008; 47: 22-30. 
[72] Chen X, McClurg A, Zhou GQ, McCaigue M, Armstrong MA, Li 
G. Chondrogenic differentiation alters the immunosuppressive 
property of bone marrow-derived mesenchymal stem cells, and the 
effect is partially due to the upregulated expression of B7 mole-
cules. Stem Cells 2007; 25: 364-70. 
 
 
Received: October 01, 2012 Revised: January 07, 2013  Accepted: January 11, 2013 
 
 
